Baert F, Wouters K, D'Haens G, Hoang P, Naegels S, D'Heygere F, Holvoet J, Louis E, Devos M, Geboes K
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Gut. 1999 Sep;45(3):375-81. doi: 10.1136/gut.45.3.375.
It is not known whether lymphocytic colitis and collagenous colitis represent different clinical entities or constitute part of a spectrum of disease.
Detailed clinical features and histological findings were compared in a large series of patients with confirmed lymphocytic and collagenous colitis.
Histological diagnosis was confirmed in 96 patients with collagenous colitis and 80 with lymphocytic colitis. Twenty eight per cent of patients with collagenous colitis and 26% of patients with lymphocytic colitis had overlapping but less pronounced histological features. Both groups were equal in terms of age, use of aspirin and non-steroidal anti-inflammatory drugs, associated autoimmune conditions, arthritis, diarrhoea, and abdominal pain. The male:female ratio was 27:73 for collagenous colitis and 45:55 for lymphocytic colitis (p=0.013). Twenty five per cent of patients with collagenous colitis compared with 14% of patients with lymphocytic colitis were active smokers; only 8.3% of patients with collagenous colitis had stopped smoking compared with 23% of patients with lymphocytic colitis (p=0.013). Drug induced disease was suspected for ticlopidine (two collagenous colitis, four lymphocytic colitis) and flutamide (four lymphocytic colitis). Mean duration of symptoms before diagnosis was two months for lymphocytic colitis and four months for collagenous colitis. Overall prognosis was generally mild; 84% of patients with lymphocytic colitis and 74% of patients with collagenous colitis reported resolution or significant improvement (p=0.033).
Collagenous and lymphocytic colitis are similar but not identical. Patients with lymphocytic colitis present somewhat earlier and are less likely to be active smokers. Symptoms are milder and more likely to disappear in lymphocytic colitis. Ticlopidine and flutamide should be added to the list of drugs inducing colitis.
淋巴细胞性结肠炎和胶原性结肠炎是不同的临床实体还是疾病谱的一部分尚不清楚。
对大量确诊为淋巴细胞性和胶原性结肠炎的患者的详细临床特征和组织学发现进行比较。
96例胶原性结肠炎患者和80例淋巴细胞性结肠炎患者的组织学诊断得到证实。28%的胶原性结肠炎患者和26%的淋巴细胞性结肠炎患者具有重叠但不太明显的组织学特征。两组在年龄、阿司匹林和非甾体抗炎药的使用、相关自身免疫性疾病、关节炎、腹泻和腹痛方面相当。胶原性结肠炎的男女比例为27:73,淋巴细胞性结肠炎为45:55(p = 0.013)。25%的胶原性结肠炎患者为现吸烟者,而淋巴细胞性结肠炎患者为14%;只有8.3%的胶原性结肠炎患者戒烟,而淋巴细胞性结肠炎患者为23%(p = 0.013)。怀疑替格瑞洛(2例胶原性结肠炎,4例淋巴细胞性结肠炎)和氟他胺(4例淋巴细胞性结肠炎)可导致药物性疾病。淋巴细胞性结肠炎诊断前症状的平均持续时间为2个月,胶原性结肠炎为4个月。总体预后一般较轻;84%的淋巴细胞性结肠炎患者和74%的胶原性结肠炎患者报告症状缓解或显著改善(p = 0.033)。
胶原性结肠炎和淋巴细胞性结肠炎相似但不完全相同。淋巴细胞性结肠炎患者症状出现稍早,现吸烟者较少。淋巴细胞性结肠炎症状较轻且更易消失。替格瑞洛和氟他胺应被列入可诱发结肠炎的药物名单。